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TNFRSF13B encodes transmembrane
activator and calcium modulator and cy-
clophilin ligand interactor (TACI), a B cell–
specific tumor necrosis factor (TNF)
receptor superfamily member. Both bial-
lelic and monoallelic TNFRSF13B muta-
tions were identified in patients with
common variable immunodeficiency
disorders. The genetic complexity and
variable clinical presentation of TACI defi-
ciency prompted us to evaluate the
genetic, immunologic, and clinical condi-
tion in 50 individuals with TNFRSF13B
alterations, following screening of
564 unrelated patients with hypogamma-
globulinemia. We identified 13 new se-
quence variants. The most frequent
TNFRSF13B variants (C104R and A181E;
n  39; 6.9%) were also present in a het-
erozygous state in 2% of 675 controls. All
patients with biallelic mutations had
hypogammaglobulinemia and nearly all
showed impaired binding to a proliferation-
inducing ligand (APRIL). However, the
majority (n  41; 82%) of the pa-
tients carried monoallelic changes in
TNFRSF13B. Presence of a heterozygous
mutation was associated with antibody
deficiency (P <.001 , relative risk 3.6). Het-
erozygosity for the most common muta-
tion, C104R, was associated with disease
(P < .001, relative risk 4.2). Furthermore,
heterozygosity for C104R was associated
with low numbers of IgDCD27 B cells
(P  .019), benign lymphoproliferation
(P < .001), and autoimmune complica-
tions (P  .001). These associations indi-
cate that C104R heterozygosity increases
the risk for common variable immunodefi-
ciency disorders and influences clinical
presentation. (Blood. 2009;113:1967-1976)
Introduction
Common variable immunodeficiency disorders (CVIDs) are the
most prevalent primary immunodeficiencies in adults, with a
frequency of about 1:25 000. They are characterized by hypogam-
maglobulinemia and a failure to mount protective antibody re-
sponses upon vaccination or pathogen exposure.1 Individuals
affected with CVIDs are susceptible to recurrent infections by
encapsulated bacteria, emphasizing the role of antibodies in the
defense against these pathogens. Other clinical problems seen at
increased frequency in CVID patients include: autoimmunity,2,3
nonmalignant lymphoproliferation (eg, splenomegaly, follicular
nodular hyperplasia of the gastrointestinal tract, and lymphadenopa-
thy),1 and malignancies, especially lymphoma and gastric cancer.1,4,5
The immunologic and cellular phenotypes of CVID patients are
manifold and the majority of patients show a perturbed antigen-
dependent terminal B-cell differentiation. Analysis of peripheral
B-cell subsets identified a reduction of switched CD27 memory
B cells as a consistent feature of the immunological phenotype in
CVID patients, which has provided a basis for disease classification
models in CVID.3,6,7
Most cases of CVID occur sporadically, but in approximately
10% of CVID cases, at least one additional family member has
either CVID or selective IgA deficiency (sIgAD).8 In the majority
of multiplex CVID families, the mode of inheritance is autosomal
dominant, but in about 20%, the mode is autosomal recessive.
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Biallelic mutations of any of the 4 genes: ICOS,9 TNFRSF13B,10,11
CD19,12 and TNFRSF13C13 have previously been shown to cause
recessive CVID. In addition, heterozygous mutations in
TNFRSF13B have been associated with CVID.10,11 The purpose of
this study was to clarify and quantify aspects of that association by
evaluating a large cohort of CVID patients.
The tumor necrosis factor receptor (TNFR) superfamily mem-
ber transmembrane activator and calcium modulator and cyclophi-
lin ligand interactor (TACI) is encoded by TNFRSF13B. TACI is
preferentially expressed on marginal zone B cells, CD27 memory
B-cell subsets, and plasma cells.14-17 It binds the 2 ligands a
proliferation inducing ligand (APRIL) and B-cell activating factor
(BAFF). These interactions induce class switch recombination
(CSR) in human and murine B cells.18-21 TACI/ mice show
impaired T cell–independent type II (TI-2) responses against
polysaccharide antigens.22 In addition, these mice spontaneously
develop lymphoproliferation and a fatal autoimmune syndrome.23
Previous studies in CVID patients have identified a variety of
sequence variants in TNFRSF13B of which the most common are
A181E and C104R.10,11,24,25 Both these variants are also seen in a
heterozygous state in healthy individuals, albeit at lower frequen-
cies.24,25 We undertook a large study to estimate the risk of CVID
associated with these monoallelic variants. We thus recruited a
cohort of 564 unrelated patients, including 433 newly described
patients, and analyzed them for TNFRSF13B mutations. We
evaluated their immunological and clinical status and assessed
whether there is any genotype/phenotype association between the
more common mutations and the different pathologies of CVIDs.
Our evaluation of the relevance for the rare mutations included:
absence of the mutation in a large collection of controls, presence
of the mutation along with a more common mutation in a
compound heterozygous state, and/or bioinformatic sequence anal-
ysis indicating that the mutation is likely to affect TACI function.
Methods
Patient and control cohorts
The study initially included 579 patients with hypogammaglobulinemia
from 564 unrelated families. Of the 579 patients, 533 patients were
diagnosed with CVID according to the European Society for Immunode-
ficiencies (ESID) criteria (see Supplemental Methods in Document S1
for diagnostic criteria; available on the Blood website; see the Supple-
mental Materials link at the top of the online article),26 41 patients
suffered from IgG subclass deficiencies, and 5 patients were diagnosed
with Good syndrome. Among the 564 index patients, 520 cases were
sporadic and 44 came from multiplex families. Among the patients, 204
originated from the United Kingdom and Ireland, 105 from Germany,
101 from the United States, 60 from Scandinavia (49 from Sweden and
11 from Norway), 46 from Italy, and 26 from Brazil and Colombia. Most
of the remaining 37 patients were from scattered locations in Europe and
were white or had incomplete country/ethnicity information. One
hundred thirty-one patients, including 72 from Germany and 48 from
Sweden were included in a cohort described in a previously published
report.25 Informed written consent was obtained from each patient or
parental guardian prior to participation, in accordance with the Declara-
tion of Helsinki. The research was conducted under the internal ethics
review board–approved research protocol no. 239/99 (ZERM, Univer-
sity Hospital Freiburg, Freiburg, Germany) and no. 186/06 (ZERM,
University Hospital Freiburg and REC Great Ormond Street Hospital
and Royal Free Hospital, London, United Kingdom).
A total of 675 healthy controls were included in this study. This control
cohort comprised 283 anonymous healthy individuals from the United
Kingdom, 100 anonymous healthy blood donors from Germany, 50 controls
from Italy, and 25 from South America. An additional 217 healthy donors
were collected from personnel and students working at or attending the
University of Freiburg. These last 217 controls were also included in a
cohort described in a previously published report.25 These participants
provided consent under a separate ethics protocol for healthy donors,
no. 186/05 (ZERM, University Hospital Freiburg and REC Great Ormond
Street Hospital and Royal Free Hospital).
We analyzed all 5 coding exons of TNFRSF13B in 579 patients. In
183 patients all exons were analyzed by direct sequencing; in 396 patients
exons 1, 2, 3, and 4 were screened for mutations by heteroduplex analysis
and subsequent sequencing, and by direct sequencing of exon 5.
In 107 control samples, all 5 coding exons of TNFRSF13B were
analyzed by direct sequencing, and TNFRSF13B exons 3 and 4 were
screened for mutations by heteroduplex analysis and subsequent sequenc-
ing in additional 568 control samples.
Heteroduplex analysis
Heteroduplex analysis was performed using fluorescence-labeled prim-
ers and conditions as previously described.27 Heteroduplex formation
was induced by mixing equal amounts of patient polymerase chain
reaction (PCR) product with a control DNA PCR product followed by
denaturation at 95°C for 5 minutes with 5°C decrements every 2 minutes
until the base holding temperature (25°C) was reached. Heteroduplex
analysis was carried out on an ABI Prism 377 DNA Sequencer (PE
Applied Biosystems, Foster City, CA) and on a MegaBACE 1000 DNA
Analyser (GE Healthcare, Chalfont St Giles, United Kingdom). The
results were analyzed using the Genetic Profiler v.2.0 software (GE
Healthcare) or GENOTYPER software (PE Applied Biosystems). Peaks
were compared with control DNA homoduplexes. Any with an abnormal
morphology (eg, split or extra peaks) were reamplified using unlabeled
primers and then sequenced.
Sequence analysis of TNFRSF13B
PCR amplification of TNFRSF13B and sequencing were performed with
primers and conditions as previously described.10 Sequence analysis was
performed with DNA Sequencing Analysis software, version 3.4 (PE
Applied Biosystems), Sequencer version 3.4.1 (Gene Codes Corporation,
Ann Arbor, MI), and BioEdit (Ibis Biosciences, Carlsbad, CA).
TACI expression
We stained 106 Epstein-Barr virus–transformed B cells28 with either a
monoclonal rat anti–human TACI antibody (1A1; Abcam, Cambridge, MA
or Alexis Biochemicals, San Diego, CA) or a biotinylated polyclonal goat
anti–human TACI antibody (Peprotech EC, London, United Kingdom)
followed by phycoerythrin (PE)–labeled goat anti–rat IgG or streptavidin-
PE or the appropriate PE-labeled isotype controls together with
CD19-PC7 (J4.119; Beckman Coulter, Paris, France). At least 104 cells,
gated according to their forward and sideward scatters, were collected on a
FACSCalibur (Becton Dickinson, Franklin Lakes, NJ) and analyzed using
FlowJo software (TreeStar, Ashland, OR).
Binding of Flag-APRIL
Staining of EBV-transformed cell lines was performed as described
previously.10 Briefly, 106 EBV-transformed cells were stained with 10-50 ng
Flag-ACRP-hAPRIL29 in the presence of 0.1 L heparin (Liquemin; Roche
Pharma, Grenzach-Wyhlen, Germany) and detected with monoclonal
mouse anti-Flag antibody M2 (Sigma, Seelze, Germany) and PE-labeled
goat anti–mouse antibodies (Caltag, Hamburg, Germany). The specificity
of Flag-ACRP-hAPRIL binding to EBV-transformed B cells was assessed
by simultaneous staining of an EBV-transformed B-cell line known to carry
a TNFRSF13B null mutation (S144X).10
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Results
Sequence analysis of TNFRSF13B in 564 index patients with
antibody deficiency
We analyzed a cohort of 564 patients with antibody deficiency and
found that 50 (8.9%) carried at least one altered TNFRSF13B allele
(Figure 1; Table 1). Of those 50 unrelated patients, 2 (4%) carried
homozygous mutations, 7 (14%) carried compound heterozygous
mutations, and 41 (82%) carried heterozygous mutations in
TNFRSF13B. One of these patients carried a double mutation
(D41H;c.298insT) on one TNFRSF13B allele. The polymorphisms
R72H (rs55916807), V220A (rs56063729), and P251L (rs34562254)
were observed in the present cohort of antibody-deficient patients
and controls at frequencies comparable to previously published
frequencies in CVID patient cohorts and healthy controls,
respectively.10,24,25
Sixteen different genetic alterations were observed, 13 of which
have not been previously described. Two new nonsense alleles and
4 frameshift mutations (3 single nucleotide insertions and 1 single
nucleotide deletion) were found. Among the 564 patients, the most
frequently mutated allele was C104R, which was present in 26
patients (4.6%), followed by the A181E allele, which was present
in 13 patients (2.3%). Only these 2 alleles were observed in a
homozygous state, each in one individual. In addition, C104R was
also present in 5 of 7 compound heterozygous mutations.
Sequence variants of TNFRSF13B in healthy subjects
A total of 675 controls were analyzed for sequence variants in
TNFRSF13B. Seven (1%) controls were heterozygous for the
A181E variant, 6 (0.9%) healthy controls were heterozygous for
the C104R allele, and 1 control was heterozygous for the I87N
allele. The missense mutations W40R, D41H, Y79C, C104Y,
A149T, G152E, and V246F were not found in the healthy control
cohort. In addition, no biallelic mutation was found in the control
cohort.
Table 2 gives estimates of the statistical significance and
relative risk of developing an antibody deficiency associated with
different types of mutations in different patient subsets relative to
the corresponding set of controls. Having a monoallelic or biallelic
mutation in TACI was strongly associated with hypogammaglobu-
linemia (P  .001; relative risk, 4.3; 95% CI 2.4-7.6). The
association of a monoallelic C104R mutation with antibody
deficiency was found to be highly significant (P  .001; relative
risk 4.2; 95% CI 1.7-10.1). In contrast, the association with the
A181E allele was not found to be statistically significant. The
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Figure 1. Mutations of TNFRSF13B in 50 of 564 index
patients with antibody deficiency. Distribution of
the observed TNFRSF13B mutations across the
TNFRSF13B/TACI protein. Each symbol represents
one patient. ● indicates patients with homozygous
TNFRSF13B mutations.  represents patients with het-
erozygous TNFRSF13B mutations. designates a pa-
tient with a double mutation on one allele of TNFRSF13B.
Compound heterozygous mutated TACI-deficient pa-
tients are labeled as indicated in the figure. CRD indi-
cates cysteine-rich domain; stalk, stalk region; and TM,
transmembrane domain.
Table 1. Mutations in TNFRSF13B
Exon NCBI_SS no. cDNA* Protein† Domain
2 10516792 c.118TC p.W40R CRD1, extracellular
10516793 c.121delG p.D41Ifs*43 CRD1, extracellular
10516794 c.121GC p.D41H CRD1, extracellular
3 10516795 c.204insA p.L69Tfs*12 CRD2, extracellular
10516796 c.236AG p.Y79C CRD2, extracellular
10516797 c.260TA p.I87N CRD2, extracellular
10516798 c.298insT p.C100Lfs*6 CRD2, extracellular
48424922 c.310TC p.C104R CRD2, extracellular
10516799 c.311GA p.C104Y CRD2, extracellular
10516800 c.445GA p.A149T Stalk region
4 10516801 c.455GA p.G152E Stalk region
10516802 c.492CA p.Y164X Stalk region
10516803 c.542CA p.A181E Transmembrane
10516804 c.571insG p.D191Gfs*46 Intracellular
10516805 c.579CA p.C193X Intracellular
5 10516806 c.736GT p.V246F Intracellular
SS indicates submitted SNP.
*NCBI nucleotide entry NM_012452.
†NCBI protein entry NP_036584.
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association of the A181E variant with CVID has, however,
previously been described as significant in an even larger cohort of
CVID patients and controls.25
Bioinformatic analysis of TACI amino acid substitutions
We carried out bioinformatic analysis of 17 amino acid substitu-
tions in TACI including those reported here and some detected only
in earlier studies (Table 3). The general aim was to predict which
changes are likely to be deleterious and, if possible, determine
which aspects of protein function (eg, the folding energy) are affected.
We used the same approach and most of the software packages used by
Thusberg and Vihinen30 to carry out a similar analysis of substitutions in
the neutropenia-associated protein ELA2.
We categorized the methods based on which aspect of the
protein they evaluate: sequence conservation, stability, disordered
regions, folding energy and contacts, steric conflicts, and aggrega-
tion of -sheets. Predictions that depend on having a protein
structure in Protein Data Bank (PDB) format31 are necessarily
limited to 5 substitutions at positions in the structure for the CRD2
domain of TACI bound to APRIL.32 The majority (11/17) of the
mutations were predicted to be deleterious by at least 2 sequence
conservation methods. Only 3 mutations, A149T, V220A, and
V246A, were predicted to be benign by all sequence conservation
methods, but V220A and V246A may disturb stability centers of
the protein. The most frequent mutation, C104R, was predicted to
lead to energy changes, an increase in disorder, and steric clashes
within the protein. Only one sequence conservation method
predicted the A181E mutation to be deleterious, but the mutation is
located at a predicted stability center of TACI. The I87N mutation
was predicted to cause energy changes and found at a stability
center of the protein. The bioinformatic analysis for TACI is less
definitive than for ELA2 because heterozygous mutations in ELA2
are generally sufficient to cause at least a cyclic form of neutrope-
nia, while heterozygous mutations in TACI may increase the risk of
developing hypogammaglobulinemia but not lead to CVID in some
carriers. Additional details and tabular results for the bioinformatic
methods can be found in Supplemental Methods in Document S1
and Tables S1 through S16.
Familial segregation
Among the 564 unrelated patients, 520 cases were sporadic and
44 were from multiplex families. In 28 families the pattern of
inheritance was autosomal dominant, in 13 the pattern was
autosomal recessive, and in 3 the pattern was undetermined.
Of the 50 index patients with mutations in TNFRSF13B, 8 had
first-degree relatives with a history of humoral immunodeficiency.
One of these families (A181E heterozygous) has been previously
reported (family 5 in Figure S1).25 The pedigrees of the remaining
7 familial cases are shown as families A through G in Figure 2 (arrows
indicate index patients) and a summary of clinical, immunological,
and genetic data for these families is shown in Table 4.
In these 7 families, 2 important observations are notable: first,
there are healthy or only mildly affected family members who have
monoallelic or biallelic mutations, therefore mutations in
Table 2. Frequencies, significance, and relative risk for any mutation, any monoallelic mutation, or heterozygous C104R in different
subsets of patients
Patient subset (n) Genotype n (%) P *
Relative risk
(95% CI)
All patients (564) Any mutation 50 (8.9)  .001 4.3 (2.4-7.6)
Sporadic patients, nonfamilial (520) Any mutation 42 (8.1)  .001 3.9 (2.2-6.9)
All patients, no biallelic mutation (555) Monoallelic mutation 41 (7.4)  .001 3.6 (2.0-6.4)
All patients, no mutation other than het. C104R (535) Heterozygous C104R 20 (3.7) .008 4.2 (1.7-10.1)
CI indicates confidence interval.
*P values are one-sided and calculated by a 2 test.
Table 3. Summary of results from 18 bioinformatics methods applied to 17 amino acid substitutions observed in TACI in either this study or
earlier studies
Substitution Seq conserv Stability center Disorder Energy change Steric clashes -Aggregation Reference
W40R XX X NA NA This study
D41H XX NA NA This study
R72H XX This study, 10,24
Y79C XX X This study
I87N XX X XX This study
C104R XX X XX X This study, 10,11,24,25,29
C104Y XX XX X This study
R122W XX X NA NA 25
A149T NA NA This study
G152E XX NA NA This study
L171R X NA NA 24,29
C172Y XX X NA NA X 29
A181E X X NA NA This study, 10,11,24,25,29
R202H X NA NA 10,11,25
V220A X NA NA This study, 10,11,24,25
V246F X NA NA This study
P251L XX NA NA This study, 10,11,24,25
For categories in which there were numerous methods, we distinguish between XX (consensus of the methods predicts that this change is deleterious), X (some methods
predict that the change is deleterious and some do not), and no mark (most if not all methods predict that the change is benign). This table is a compilation of summaries of
results that can be found in Tables S1 through S16.
Seq conserv indicates sequence conservation; and NA, not available.
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TNFRSF13B are not 100% penetrant; and second, CVID patients
E.II.1 and F.I.2 have 2 wild-type TNFRSF13B alleles, hence these
patients teach us that mutations in TACI are a contributing factor to
develop CVID but are not solely causative. More clinical informa-
tion on the families can be found in Table 4 and Supplemental
Results in Document S1.
TACI expression and APRIL binding
EBV-transformed B-cell lines were established from 25 patients
with mutations in TNFRSF13B, 5 CVID patients with wild-type
alleles of TNFRSF13B, and 5 healthy controls. These cell lines
were analyzed for TACI expression and for binding of APRIL. An
additional EBV-transformed cell line, homozygous for a stop
codon mutation, S144X, and previously shown to lack TACI
expression,10 served as a negative control. EBV-transformed cells
were stained with (1) a polyclonal Ab directed against the
extracellular domain of TACI, (2) a monoclonal Ab (mAb; clone
1A1), which requires Cys 104 for TACI recognition, and (3) the
fluorescence-tagged APRIL.
Surface expression of TACI in EBV-transformed cell lines from
controls was readily detected (Figure 3A) but was variable in
controls and in patients. In all cases it was much higher than that of
the negative homozygous S144X control. Cell lines from CVID
patients without a mutation in TACI and healthy donors were used
as controls (Figure 3A).
In 2 EBV-transformed cell lines with homozygous C104R
mutations (from a newly identified patient and one from a
previous report10), the binding of APRIL and of the mAb 1A1
were completely abolished (Figure 3A). This was expected as
TACI C104R has previously been shown to be defective in
APRIL binding, and because Cys 104 is part of the epitope
recognized by mAb 1A1.10 Staining of C104R homozygous
B-cell lines with the polyclonal antibody was reduced 2- to
3-fold on average when compared with wild type, suggesting
that this mutation in a homozygous state also impairs surface
expression of TACI (Figure 3A), or influences the stability of the
protein. It is unlikely that this reduced staining results from
decreased binding of the polyclonal antibody to TACI C104R,
but indeed reflects reduced surface expression of the TACI
C104R mutant. This was demonstrated by the reduced staining
of the polyclonal antibody in 293T cells transfected with TACI
C104R full-length constructs and the unimpaired staining of
cells expressing a TACI-C104R-TRAIL-R3 fusion protein (Fig-
ure S3). More details on this experiment can be found in
Supplemental Methods and Results in Document S1.
The analysis of 12 cell lines with the heterozygous C104R
mutation revealed TACI surface expression by all 3 staining
techniques but with a lower average staining intensity compared
with TACI wild-type controls. These results are consistent with the
surface expression of both wild-type TACI and C104R TACI. The
Figure 2. Pedigrees of familial TACI deficiency. Pedi-
grees of 7 families with TACI deficiency are shown.
Symbols: circles indicate female; squares, male; black
filled symbols, CVID; gray filled symbols, IgG subclass
deficiency or dysgammaglobulinemia; hatched symbols,
selective IgA deficiency; slash, deceased; and arrow,
index patient. Mutations shown in brackets are inferred.
§IDs refer to Voerechovsky et al.33
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results are also consistent with wild-type TACI staining with mAb
anti-TACI (1A1) and with Flag-APRIL, while the mutated C104R
allele was stained with neither. This also indicates that the TACI
C104R allele does not interfere with surface expression and APRIL
binding of the coexpressed wild-type TACI.
Single EBV-transformed cell lines carrying heterozygous frameshift/
nonsense mutations (c.121delG; c.204insA; C193X) or the heterozy-
gous missense mutation A181E displayed no significant differences in
TACI expression and ligand-binding capacity compared with controls
(Figure S1). A slight but specific decrease of APRIL binding was
observed in the 2 I87N heterozygotes, suggesting that these mutant cells
have a decreased binding of APRIL (Figure S1).
There were 5 EBV-transformed cell lines from CVID pa-
tients with compound heterozygous TNFRSF13B mutations
available for testing; all showed severely impaired APRIL
binding, despite surface expression of TACI (Figure 3B). It is
noteworthy that the Y79C and I87N mutations are located in the
ligand-binding domain of TACI (CRD2; Figures 1 and S2), and
although these residues do not mediate direct contacts with
APRIL,32 they may disturb the protein architecture, preventing
APRIL binding.
Interestingly, the compound heterozygous mutations involving
C104R in combination with a frameshift or nonsense mutation
resemble closely the staining pattern that is seen in EBV-
transformed cell lines carrying a C104R homozygous mutation
(Figure 3B). This suggests that the frameshift or nonsense alleles
are not expressed at the cell surface.
B-cell phenotype and immunoglobulin levels in TACI-deficient
individuals
The CD19 B-cell percentage of total blood lymphocytes was
analyzed in 45 of the 50 index patients with TNFRSF13B mutations
(Figure 4A left panel). B cells were present at normal percentages
(6%-19% of lymphocytes) in the majority of patients (25 of 45).
Severe B-cell lymphopenia ( 1%) was only identified in 1 of the
45 patients (c.121delG). This patient also showed a relative
expansion of transitional IgDIgMCD24CD38 B cells
(26.1% of B cells).
B-cell subset analysis was available for 37 of the 50 patients
(Figure 4A right panel). IgDIgMCD27 switched memory
B cells were reduced in 28 of the 37 patients (76%) and below 2%
of total B cells in 18 of the 37 analyzed patient samples (49%). This
is comparable to the B-cell phenotypes of CVID patients in
general.3,6 The proportion of IgDIgMCD27 memory B cells
and IgDIgMCD27 naive B cells varied considerably among
patients. In particular, 13 of 17 (76%) C104R heterozygous patients
had switched memory B cells below 2% of total B cells, whereas
only 2 of 9 patients with homozygous or compound heterozygous
mutations in TNFRSF13B were found to have switched memory
B cells below 2% of total B cells. The difference in percentages of
switched memory B cells was found to be significant, when the
C104R heterozygous patient group was compared with the patients
carrying 2 mutated TNFRSF13B alleles (P  .019; Student t test).
Serum IgG levels were available at diagnosis and/or prior to the
onset of IgG substitution therapy for 40 of 50 patients (Figure 4B);
Table 4. Families with mutations in TNFRSF13B
Family Individual Age, y Affection status TNFRSF13B mutation IgG, g/L IgA, g/L IgM, g/L
A I.1 42 Healthy C104R 12.9 0.83 1.24
I.2 40 Healthy C104Y 12.04 1.6 0.82
II.1 14 CVID C104R/C104Y 2.87 0.06 0.14
II.2 4 CVID C104R/C104Y 3.59 0.12 0.19
B I.1 55 Dysgamma I87N* 5.5 0.36 0.99
I.2 54 Healthy Y79C 7.6 1.4 1.3
II.1 33 IgG subclass deficiency Y79C/I87N 5.9 1.1 1.3
II.2 32 IgG subclass deficiency Y79C/I87N 5.6 0.9 0.5
C II.1 53 CVID c.204insA/C104R 2.30 0.23 0.31
III.1 37 IgG1 subclass deficiency c.204insA 5.94 0.69 1.31
D I.2 66 CVID C104R 3.31 0.07 1.18
II.1 36 Dysgamma C104R 7.14 0.34 0.64
II.2 32 CVID C104R 3.4 0 0.23
III.1 6 Healthy wt 7.43 0.58 0.36
III.2 4 Dysgamma wt 5.53 0.24 0.53
E(cv78) I.1 87 SIgAD unknown 16.0 0 3.6
I.2 77 Healthy wt 12.0 1.05 0.7
II.1 52 CVID wt 8.8† 0.1 0.1
II.2 57 CVID C104R 7.4† 0.1 0.1
II.3 56 SIgAD wt 16.0 0 1.6
II.4 54 SIgAD wt 15.0 0 1.6
F(cv132) I.1 61 Healthy A181E NA NA NA
I.2 56 CVID wt 9.2† 0.1  0.1
II.1 19 CVID A181E 2.73 0.17 0.25
II.2 26 Healthy A181E 7.8 2.0 0.9
G I.1 34 Healthy wt 9.78 4.86 0.81
I.2 32 Healthy D41H;c.298insT 14.92 3.23 2.11
II.1 9 CVID D41H;c.298insT 0.19 0.02 3.51
II.2 1 Healthy D41H;c.298insT 8.98 0.62 0.71
Patients and relatives were assigned to their respective affection status as being healthy, or having sIgAD, dysgamma, IgG subclass deficiency, or CVID.
Values below normal range for age are printed in italics. Dysgamma indicates dysgammaglobulinemia; wt, wild type; and NA, not available.
*This mutation was inferred.
†IgG level while the patient received intravenous immunoglobulin substitution therapy.
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these IgG levels showed major variation between patients. In
11 patients the total IgG level was below 1 g/L at the time of
diagnosis, whereas 4 patients had IgG levels of about 5 g/L at the
time of diagnosis. IgA and IgM levels were available for 46 patients
(Figure 4B). IgA was deficient ( 0.07 g/L) in 25 patients, low
(0.07-0.7 g/L) in 18 patients, and normal in 3 patients. Of the
patients with normal IgA levels (0.07-4.0 g/L), one carried a
compound heterozygous Y79C/I87N mutation, one had a heterozy-
gous I87N mutation, and the third had a C104R heterozygous
mutation. IgM was low in 31 patients ( 0.4 g/L), normal in
12 patients (0.4-2.3 g/L), and elevated ( 2.3 g/L) in 3 patients. Of
the 3 patients with elevated IgM levels, all had CVID and one had a
C104R heterozygous mutation, the second had a homozygous
A181E mutation, and the third carried the double mutation
(D41H;c.298insT).
Clinical phenotypes observed in TACI-deficient individuals
Among all index patients, 540 were evaluated for the presence
of autoimmunity. Of these, 130 (24%) had at least one autoim-
mune manifestation. A total of 542 patients were evaluated for
the presence of lymphoproliferation, which was found in 202 of
these patients (37%). All patients suffered from recurrent
infections as a consequence of the hypogammaglobulinemia. In
the index patients with a wild-type TACI sequence, autoimmu-
nity was present in 112 of 490 (23%), and lymphoproliferation
was found in 172 of 492 (35%). In the TACI-mutated patient
cohort, autoimmunity was present in 18 of 50 patients (36%;
P  .029) and signs of lymphoproliferation were present in
30 of 50 patients (60%; P  .001) (Figure 5). Clinical details on
all 50 TACI-deficient patients can be found in Table S17.
Splenomegaly was the predominant sign of lymphoproliferation
(22 patients). Other manifestations of lymphoproliferation were
persistent lymphadenopathy (13 patients) and nodular lymphatic
hyperplasia in the gut (2 patients). Eleven patients showed more
than one feature of lymphoproliferation. Malignant lymphopro-
liferation was noted in 4 CVID patients with mutated TACI. One
patient developed a cerebral lymphoma, a second had a low-
grade malignant B-cell lymphoma, a third had T-cell lymphoma,
and a fourth suffered from B-cell non-Hodgkin lymphoma and
T-cell lymphoma. Three of the 4 patients carried heterozygous
A181E mutations; the fourth carried a heterozygous C104R
mutation. Notably, one A181E heterozygous patient reported
by Castigli et al11 also suffered from a B-cell non-Hodgkin
lymphoma.
The most prevalent autoimmune disease was autoimmune
thrombocytopenia (ITP), seen in 7 patients. Other autoimmune
manifestations included autoimmune hemolytic anemia (3 pa-
tients), the presence of anti-IgA antibodies (2 patients), vitiligo,
diabetes mellitus, celiac disease, arthritis, autoimmune urticaria,
autoimmune hepatitis, and recurrent parotitis (one patient each).
Figure 3. TACI expression and APRIL binding on
EBV-transformed cell lines. (A) The histograms show
the mean fluorescence intensity (MFI) of stainings of
EBV-transformed B-cell lines with a polyclonal antibody
against TACI (left), a monoclonal antibody recognizing
the TACI extracellular domain (clone 1A1; middle), and a
Flag-tagged recombinant APRIL construct.  indicates
C104R homozygous (n  2); , C104R heterozygous
(n  12); , healthy donors (n  5); and , CVID
patients without TNFRSF13B mutation (n  5). The
thick gray line in each graph indicates the background
staining of a previously described homozygous S144X
cell line.10 Mean values and SDs are shown at the right
side of the scatter diagram of each group. Testing for
significance was performed with the Student t test. (B)
TACI expression and APRIL binding on EBV-trans-
formed cell lines with homozygous or compound het-
erozygous TNFRSF13B mutations, stained with a poly-
clonal antibody directed against the TACI extracellular
domain (top panels), stained with a monoclonal antibody
recognizing the TACI extracellular domain (middle pan-
els), and stained with a Flag-tagged APRIL construct
(bottom panels). Thick black lines indicate patients; thick
dashed black lines, healthy donors; and gray filled
histograms, patients with TNFRSF13B null mutation
(S144X homozygous, negative control).
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These findings are comparable to previously reported surveys of
CVID patients in general.1,3,34
However, most patients with autoimmunity and a TACI muta-
tion (12 of 18) and with lymphoproliferation and a TACI mutation
(21 of 30) carried at least one C104R allele (Figure 5). The
prevalence of autoimmunity was significantly higher (P  .001) in
the TNFRSF13B C104R heterozygous group than the group of
patients with a wild-type TNFRSF13B sequence (Figure 5 top
histogram). The prevalence of lymphoproliferation was also signifi-
cantly higher (P  .001) in the C104R heterozygous group than in
the patient groups with no mutation in TNFRSF13B (Figure 5
bottom histogram).
Discussion
In previous studies, the proportion of CVID patients carrying at
least one TNFRSF13B mutation was estimated at 10 to 20%.10,11 Of
a cohort of 564 antibody deficiency patients in the present study,
50 patients had at least one TACI allele mutated, yielding a more
precise estimate of 9%. We confirmed the previous hypothesis that
biallelic TNFRSF13B mutations are not found in healthy individu-
als; however, it should be noted that individuals with some biallelic
mutations such as homozygous S144X10 and Y79C/I87N do not
meet all current criteria for a diagnosis of CVID and may be clinically
well. We identified 13 new mutations, including 5 nonsense and
frameshift mutations. One limitation of this study is that we sequenced
only exons of TNFRSF13B and the intron-exon borders; patients
may have had mutations in the promoter or in regulatory sequences
in introns that went undetected.
In our large CVID cohort, the only significant association of a
specific TACI variant with CVID was that of TACI C104R
(P  .001). Other sequence variants, including frameshift and
nonsense mutations, were often observed only in single individuals
and thus were too rare to reach statistical significance. Functional
studies have demonstrated that the C104R variant impairs the
function of TACI both in homozygous and heterozygous states.10,35
Heterozygous TNFRSF13B C104R is associated with CVID, but
neither this mutation nor any other heterozygous mutation in
TNFRSF13B can explain a sufficient percentage of the multiplex
CVID families with dominant inheritance.
Although TACI expression on human peripheral blood B cells
correlates well with the expression of CD27,14,17 we observed that
TACI does not seem to be required for the development of memory
B cells in humans. Several TACI-deficient patients accumulate
normal numbers of switched and nonswitched memory B cells,
including one hypogammaglobulinemic individual with a previ-
ously described TNFRSF13B null mutation (S144X)10 and a CVID
patient with a compound heterozygous mutation presented here
(C104R/c.204insA).
The IgG levels at diagnosis or prior to intravenous immunoglobu-
lin therapy were low in the majority of TACI-deficient patients.
Agammaglobulinemia (total Ig 1 g/L) was observed in 7 pa-
tients. IgA was the most severely affected isotype, which is typical
for CVID and also consistent with our previous findings in patients
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Figure 4. Immunologic phenotype of TACI-deficient patients.
(A) CD19 B-cell percentages of lymphocytes and IgDIgMCD27,
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with TACI deficiency.10 However, 3 patients with TNFRSF13B
mutations had normal IgA levels at the time of diagnosis, which
was based partly on low IgG levels. This suggests that in humans,
switching to IgA can still occur when the APRIL-TACI interaction
is impaired, in contrast to the findings in APRIL/ mice.21 The
BAFF receptor (BAFFR), another member of the TNFR superfam-
ily, is also unlikely to be the major factor in class switching to IgA
because BAFF-R–deficient mice and humans are capable of
switching to IgA and have normal IgA levels in serum.13,36 In
contrast to our initial study,10 the IgM levels in this cohort of
TACI-deficient CVID patients were less affected, and we found
3 patients with elevated IgM serum levels at the time of diagnosis.
Because TACI-knockout mouse models show a prominent
autoimmune phenotype and massive signs of lymphoprolifera-
tion,23 it has been speculated that human TACI deficiency in
CVID patients is primarily associated with these features. In our
initial study, 5 of 13 patients (38%) showed signs of autoimmu-
nity.10 However, most of the autoimmune phenomena observed
were mild (vitiligo, anti-IgA antibodies, autoimmune thyroid-
itis). Castigli et al11 reported no autoimmune phenomena in their
4 CVID patients with TNFRSF13B mutations. Zhang et al37
observed a higher prevalence of ITP in 6 of 13 TACI-deficient
CVID patients (46%; 5/10 heterozygotes and 1/3 compound
heterozygotes) versus 20 of 163 CVID patients without
TNFRSF13B mutations (12%), but they did not compare the
incidence of types of autoimmunity other than ITP.
Our current results suggest a more complex association of
TNFRSF13B mutations and autoimmunity. Many types of autoimmu-
nity other than ITP are seen in patients with TACI mutations, although
ITP may be particularly common in C104R heterozygotes. The preva-
lence of autoimmunity is significantly lower (1/9, 11%) in patients with
biallelic mutations in TNFRSF13B than in patients with the specific
monoallelic mutation C104R (11/20, 55%; 2-sided P .04; Fisher
exact test). We speculate that the higher rate of autoimmunity in TACI
heterozygotes arises because the wild-type TACI allele in heterozygotes
may be able to promote the survival of autoreactive B-cell clones better
than any of the 2 mutated TACI alleles available in individuals with
biallelic mutations.
We have previously shown that individuals with homozygous
TNFRSF13B mutations have a selective impairment of APRIL
binding, APRIL induced B-cell proliferation, and CSR.10 Every cell
line that we have studied from patients with compound heterozy-
gous mutations failed to bind APRIL. Hence, it is assumed that
primary B cells from patients with biallelic mutations do not
respond to APRIL-mediated stimuli either.
The effects of heterozygous sequence variants are less clear.
The recruitment of a TACI mutant in the APRIL signaling complex
may exert a dominant-negative effect by disturbing the 3-fold
symmetry required for proper signaling.29,31 However, as TACI
C104R does not bind APRIL, a dominant negative effect would
require preassociation of TACI C104R with wild-type TACI in a
ligand-independent manner, as suggested by the recent report of
Garibyan et al.35 In support of this model, we demonstrate surface
expression of TACI in cell lines derived from patients with
homozygous TACI C104R mutations. Thus, in heterozygous
patients, TACI C104R will most likely be coexpressed at the
surface with wild-type TACI. TACI was recently shown to respond
to oligomeric BAFF or APRIL only, implying that at least
6 wild-type receptors are likely to be required in an active signaling
complex,38 rendering the system particularly sensitive to dominant-
negative effects of mutated receptors.
In summary, we found that about 9% of patients with antibody
deficiency carry at least one mutated TNFRSF13B allele, and
nearly 2% carry biallelic mutations. These estimates are consistent
with previous studies, but are now based on a larger sample.
Homozygous or compound heterozygous mutations in TNFRSF13B
were exclusively found in individuals with clinical or immunologi-
cal features of antibody deficiency. Incomplete penetrance and
familial segregation were, however, demonstrated for heterozygous
TNFRSF13B sequence variants and imply that heterozygous muta-
tions increase the risk, but are neither necessary nor sufficient to
cause CVID. Further studies are needed to unravel the additional
genetic and environmental factors that act in concert with simple
heterozygous genetic alterations in TNFRSF13B to give rise to
antibody deficiencies in humans.
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